Malignant lymphoma (ML) is a heterogeneous malignant tumor in the hematological system, the existing treatment methods can not meet the clinical needs, and the rapid rise of new treatment schemes has improved the survival benefits of patients with recurrent or refractory ML. Antibody-drug conjugate (ADC), as a new type of highly effective anti-tumor drug composed of monoclonal antibodies specifically targeting tumor cell surface antigens, coupled with small molecular cytotoxic loads through chemical connectors, has attracted much attention in the application prospect of malignant lymphoma. Several ADCs have been approved for the treatment of ML, including brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, polatuzumab vedotinands, loncastuximab tesirine, etc. These drugs can exert anti-tumor effects by targeting CD30, CD22, CD79b, CD19, etc. on the surface of tumor cells with good efficacy and safety.